2.700SEK-1.10%Mkt Cap: 655.38M SEKP/E: —Last update: 2026-06-01
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses …
Industry Peers
Drug Manufacturers - Specialty & Generic150.78BSEKP/E 166.4
58.93BTRY—
56.89BEURP/E 22.4
32.78BPLNP/E 21.4
23.20BUSDP/E 20.2
18.39BUSD—
16.21BUSDP/E 24.8
13.00BTRY—
Indicators:|
Key Statistics
Company
Market Cap655.38M SEK
Enterprise Value637.27M SEK
Revenue (TTM)53.06M SEK
Gross Profit33.13M SEK
Net Income (TTM)-51.89M SEK
Revenue/Share0.2190 SEK
Last Price2.700 SEK
Fiscal Year EndMar 2021
MR QuarterMar 2026
Employees21
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0003943620
Valuation
P/E (Trailing)—
P/E (Forward)-9.10
PEG—
EV/EBITDA-14.33
EV/Revenue12.01
P/S12.49
P/B5.97
EPS (TTM)-0.20
EPS (Forward)-0.30
52W Range
1.60061% of range3.400
52W High3.400 SEK
52W Low1.600 SEK
Profitability
Gross Margin61.45%
Oper. Margin-118.64%
EBITDA Margin-83.82%
Profit Margin-96.27%
ROE-41.79%
ROA-36.55%
Growth
Revenue Growth-6.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-40.97M SEK
CapEx (TTM)231.00K SEK
FCF Margin-41.85%
FCF Yield-3.39%
Net Debt-25.39M SEK
Net Debt/EBITDA0.57
Balance Sheet
Debt/Equity0.01
Current Ratio3.05
Quick Ratio2.09
Book Value/Sh0.4570 SEK
Cash/Share0.1070 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.242.74M
Float106.48M
Insiders69.40%
Institutions4.33%
Technical
SMA 502.704 (-0.2%)
SMA 2002.206 (+22.4%)
Beta-0.37
S&P 52W Chg27.70%
Avg Vol (30d)92.41K
Avg Vol (10d)89.29K
Technical Indicators
RSI (14)56.2
MACD0.0103
MACD Signal-0.0227
MACD Hist.+0.0330
BB Upper2.835 SEK
BB Middle2.560 SEK
BB Lower2.285 SEK
BB Width21.48%
ATR (14)0.1971 SEK
Vol Ratio (20d)0.92x